Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
Spectrum Pharmaceuticals, Inc
Spectrum Pharmaceuticals, Inc
EVIVE Biotechnology
EVIVE Biotechnology
Spectrum Pharmaceuticals, Inc
Spectrum Pharmaceuticals, Inc
Viatris Inc.
EVIVE Biotechnology
Peking University
Canadian Cancer Trials Group
Tianjin SinoBiotech Ltd.
EVIVE Biotechnology
Wake Forest University Health Sciences
Xiamen Amoytop Biotech Co., Ltd.
Sandoz
Tianjin SinoBiotech Ltd.
Sandoz
Biocad
Biocad
BioLab 612 LLC
Sandoz
Jiangsu HengRui Medicine Co., Ltd.
Amgen
Jiangsu HengRui Medicine Co., Ltd.
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
Amgen
Amgen
Amgen
Amgen
National Institutes of Health Clinical Center (CC)